๐๐ฎ๐ฟ ๐๐น๐ฑ๐ฎ๐๐ฎ ๐ฎ๐ป๐ฑ ๐ข๐ก๐๐ผ๐ป๐ฐ๐ฒ๐ฝ๐ยฎ ๐๐ป๐ป๐ผ๐๐ป๐ฐ๐ฒ ๐๐
๐ฐ๐น๐๐๐ถ๐๐ฒ ๐๐ถ๐ฐ๐ฒ๐ป๐๐ถ๐ป๐ด ๐๐ด๐ฟ๐ฒ๐ฒ๐บ๐ฒ๐ป๐ ๐๐ผ ๐๐
๐ฝ๐ฎ๐ป๐ฑ ๐๐ฐ๐ฐ๐ฒ๐๐ ๐๐ผ ๐ข๐ป๐ฐ๐ผ๐น๐ผ๐ด๐ ๐ง๐ฟ๐ฒ๐ฎ๐๐บ๐ฒ๐ป๐ ๐ถ๐ป ๐ ๐๐ก๐โ
โ
Amman, Jordan / Coimbra, Portugal โ 23 June 2025 โ Dar Aldawa, a leading pharmaceutical company in the Middle East and North Africa (MENA) region, and ONConceptยฎ, a strategic consortium in the field of oncology, have entered into an exclusive licensing and supply agreement for a key oncology product. The agreement was officially signed at Dar Aldawaโs headquarters in Amman, Jordan, on 11 May 2025 by Dr. Khaled Harb, CEO of Dar Aldawa, Dr. Sรฉrgio Simรตes of Bluepharma and Dr. Lars Hallmayer of Welding.โ
โ
Under the terms of the agreement, Dar Aldawa will oversee the productโs registration, commercialization, and distribution throughout the MENA region, while ONConceptยฎ Consortium will be the exclusive supplier, with production at Bluepharmaโs facilities in Portugal. This strategic partnership is aimed at increasing access to high-quality oncology treatments across the region, responding to a rising demand for effective and affordable cancer therapies.โ
โ
๐๐ฟ. ๐๐ต๐ฎ๐น๐ฒ๐ฑ ๐๐ฎ๐ฟ๐ฏ, ๐๐๐ข ๐ผ๐ณ ๐๐ฎ๐ฟ ๐๐น๐ฑ๐ฎ๐๐ฎ ๐๐ฟ๐ผ๐๐ฝ, ๐๐๐ฎ๐๐ฒ๐ฑ:โ
“We are pleased to partner with ONConceptยฎ to reinforce our oncology portfolio and reinforce our presence in a critical therapeutic area. This collaboration reflects our commitment to providing reliable, high-quality treatment options that meet the evolving needs of healthcare systems and patients in the region.”โ
โ
๐ข๐ป ๐ต๐ถ๐ ๐ฏ๐ฒ๐ต๐ฎ๐น๐ณ, ๐ฆ๐ฒฬ๐ฟ๐ด๐ถ๐ผ ๐ฆ๐ถ๐บ๐ผฬ๐ฒ๐, ๐ฉ๐ถ๐ฐ๐ฒ-๐ฃ๐ฟ๐ฒ๐๐ถ๐ฑ๐ฒ๐ป๐ ๐ผ๐ณ ๐๐น๐๐ฒ๐ฝ๐ต๐ฎ๐ฟ๐บ๐ฎ, ๐ฐ๐ผ๐บ๐บ๐ฒ๐ป๐๐ฒ๐ฑ:โ
“This collaboration represents a strategic partnership that extends beyond product distribution โ it aligns two organizations with a shared vision for improving healthcare in the region. By combining ONConceptยฎโs expertise in high-quality pharmaceutical development with Dar Aldawaโs deep understanding of the local healthcare landscape, we are creating a foundation for long-term impact in a critical therapeutic area. This agreement reinforces our commitment to expanding access to effective oncology treatments and building sustainable value for patients, providers, and health systems.โ
This agreement underscores the companiesโ shared dedication to quality, access, and long-term value for healthcare stakeholders across the MENA region.
